155 related articles for article (PubMed ID: 16651699)
21. Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents.
Sancilio LF; Pinkus LM; Jackson CB; Munson HR
Eur J Pharmacol; 1990 Jun; 181(3):303-6. PubMed ID: 2384137
[TBL] [Abstract][Full Text] [Related]
22. Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret.
King GL; Landauer MR
J Pharmacol Exp Ther; 1990 Jun; 253(3):1026-33. PubMed ID: 2359014
[TBL] [Abstract][Full Text] [Related]
23. Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs.
Yamakuni H; Sawai H; Maeda Y; Imazumi K; Sakuma H; Matsuo M; Mutoh S; Seki J
J Pharmacol Exp Ther; 2000 Mar; 292(3):1002-7. PubMed ID: 10688616
[TBL] [Abstract][Full Text] [Related]
24. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
[TBL] [Abstract][Full Text] [Related]
25. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
Youssefyeh RD; Campbell HF; Klein S; Airey JE; Darkes P; Powers M; Schnapper M; Neuenschwander K; Fitzpatrick LR; Pendley CE
J Med Chem; 1992 Mar; 35(5):895-903. PubMed ID: 1312602
[TBL] [Abstract][Full Text] [Related]
26. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint?
Koizumi W; Tanabe S; Nagaba S; Higuchi K; Nakayama N; Saigenji K; Nonaka M; Yago K
Chemotherapy; 2003 Dec; 49(6):316-23. PubMed ID: 14671433
[TBL] [Abstract][Full Text] [Related]
27. Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret.
Warneck JB; Cheng FH; Barnes MJ; Mills JS; Montana JG; Naylor RJ; Ngan MP; Wai MK; Daiss JO; Tacke R; Rudd JA
Toxicol Appl Pharmacol; 2008 Nov; 232(3):369-75. PubMed ID: 18675289
[TBL] [Abstract][Full Text] [Related]
28. [A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin].
Tsukuda M; Mochimatsu I; Furukawa M; Kohno H; Kawai S; Enomoto H; Yago T; Matsuda H; Ikema Y; Zhou L
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1959-67. PubMed ID: 7487127
[TBL] [Abstract][Full Text] [Related]
29. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
30. Antiemetic effects of YM060, a potent and selective serotonin (5HT)3-receptor antagonist, in ferrets and dogs.
Kamato T; Miyata K; Ito H; Yuki H; Yamano M; Honda K
Jpn J Pharmacol; 1991 Nov; 57(3):387-95. PubMed ID: 1813664
[TBL] [Abstract][Full Text] [Related]
31. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
Endo T; Sugawara J; Nemoto M; Minami M; Blower PR
Res Commun Mol Pathol Pharmacol; 1998 Dec; 102(3):227-39. PubMed ID: 10342910
[TBL] [Abstract][Full Text] [Related]
32. Studies on the emetic and antiemetic properties of zacopride and its enantiomers.
Sancilio LF; Pinkus LM; Jackson CB; Munson HR
Eur J Pharmacol; 1991 Jan; 192(3):365-9. PubMed ID: 2055236
[TBL] [Abstract][Full Text] [Related]
33. [Serotonin and anticancer drug-induced emesis].
Minami M; Endo T; Hamaue N; Hirafuji M
Yakugaku Zasshi; 2004 Aug; 124(8):491-507. PubMed ID: 15297719
[TBL] [Abstract][Full Text] [Related]
34. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
35. The actions of fenfluramine and interaction with 5-HT3 receptor-antagonists to inhibit emesis in the ferret.
Costall B; Naylor RJ; Tattersall FD
J Pharm Pharmacol; 1990 Feb; 42(2):94-101. PubMed ID: 1972409
[TBL] [Abstract][Full Text] [Related]
36. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
37. Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet.
Grélot L; Le Stunff H; Milano S; Blower PR; Romain D
J Pharmacol Exp Ther; 1996 Oct; 279(1):255-61. PubMed ID: 8859001
[TBL] [Abstract][Full Text] [Related]
38. DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog.
Yoshida N; Omoya H; Ito T
J Pharmacol Exp Ther; 1992 Mar; 260(3):1159-65. PubMed ID: 1532032
[TBL] [Abstract][Full Text] [Related]
39. Ethanol-induced emesis in the house musk shrew, Suncus murinus.
Chen Y; Saito H; Matsuki N
Life Sci; 1997; 60(4-5):253-61. PubMed ID: 9010480
[TBL] [Abstract][Full Text] [Related]
40. Effects of granisetron, a 5-HT3 receptor antagonist, on 5-hydroxytryptamine (5-HT) release from the isolated ileum in a delayed-emesis rat model.
Endo T; Hamaue N; Ihira E; Teramoto Y; Liu Y; Hirafuji M; Minami M
Res Commun Mol Pathol Pharmacol; 2002; 111(1-4):55-68. PubMed ID: 14632314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
